Here, we report the draft genome sequence of Clostridium termitidis strain CT1112 (DSM 5398), a mesophilic, cellulolytic bacterium that can utilize a variety of sugars, as well as pure cellulose, as a sole carbon source; it also synthesizes fermentation end products with potential industrial applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662827 | PMC |
| http://dx.doi.org/10.1128/genomeA.00281-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Draft genome sequencing of a multidrug-resistant strain MBBL2 isolated from mastitic cow milk.
Microbiol Resour Announc
January 2025
Molecular Biology and Bioinformatics Laboratory, Department of Gynecology, Obstetrics and Reproductive Health, Bangabandhu Sheikh Mujibur Rahman Agricultural University (BSMRAU), Gazipur, Bangladesh.
Milk from cows with mastitis is a primary source of bacteria harboring antibiotic resistance genes (ARGs), including . We present the genome sequence of strain MBBL2 isolated from mastitic cow milk, which contains numerous ARGs and virulence-associated genes potentially pathogenic to humans.
View Article and Find Full Text PDFDraft genome sequencing of multidrug-resistant strains isolated from mastitic cow milk.
Microbiol Resour Announc
January 2025
Molecular Biology and Bioinformatics Laboratory, Department of Gynecology, Obstetrics and Reproductive Health, Bangabandhu Sheikh Mujibur Rahman Agricultural University (BSMRAU), Gazipur, Bangladesh.
is an important antibiotic-resistant pathogen in mastitis, with broader public health implications. We report the genomes of two strains, MBBL4 and MBBL5, isolated from mastitic cow milk. The draft genomes, covering 4.
View Article and Find Full Text PDFDraft genome sequences of eight strains isolated from homemade yogurts and cheeses from Bulgaria.
Microbiol Resour Announc
January 2025
Advanced Microbiotics, Stans, Switzerland.
Here, we report draft genome sequences of eight strains isolated from naturally processed, homemade dairy foods or human milk in Bulgaria; strains AM-LG-29, AM-LP-81, AM-LH-32, subsp. AM-LB-13, AM-ST-89, AM-LA-19, AM-BL-55, and AM-LR-51.
View Article and Find Full Text PDFIdentification of strengths and weaknesses of the healthcare system for persons living with rare diseases in Catalonia (Spain), and recommendations to improve its comprehensive attention: the "acERca las enfermedades raras" project.
Orphanet J Rare Dis
January 2025
Laboratory of Neurogenetics and Molecular Medicine, Center for Genomic Sciences in Medicine, Institut de Recerca Sant Joan de Déu, Únicas SJD Center, Hospital Sant Joan de Déu, Barcelona, Spain.
Background: Rare diseases (RDs) are a heterogeneous group of complex and low-prevalence conditions in which the time to establish a definitive diagnosis is often too long. In addition, for most RDs, few to no treatments are available and it is often difficult to find a specialized care team.
Objectives: The project "acERca las enfermedades raras" (in English: "bringing RDs closer") is an initiative primary designed to generate a consensus by a multidisciplinary group of experts to detect the strengths and weaknesses in the public healthcare system concerning the comprehensive care of persons living with a RD (PLWRD) in the region of Catalonia, Spain, where a Network of Clinical Expert Units (Xarxa d'Unitats de Expertesa Clínica or XUEC) was created and is being implemented since 2015.
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Mol Diagn Ther
January 2025
Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON, N6A 5B7, Canada.
Clinical endpoints caused by hyperlipoproteinemia include atherosclerotic cardiovascular disease and acute pancreatitis. Emerging lipid-lowering therapies targeting proprotein convertase subtilisin/kexin 9 (PCSK9), lipoprotein(a), apolipoprotein C-III, and angiopoietin-like protein 3 represent promising advances in the management of patients with hyperlipoproteinemia. These therapies offer novel approaches for lowering pathogenic lipid and lipoprotein species, particularly in patients with serious perturbations who are not adequately controlled with conventional treatments or who are unable to tolerate them.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!